ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2013
Drug treatment of acute ischemic stroke.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- The protective effects of ligustrazine on ischemic stroke: a systematic review and meta-analysis of preclinical evidence and possible mechanisms.Frontiers in pharmacology · 2024Pooled it
- Effectiveness of interventions to improve rates of intravenous thrombolysis using behaviour change wheel functions: a systematic review and meta-analysis.Implementation science : IS · 2020Pooled it
- Stem Cell-Based Therapies via Different Administration Route for Stroke: A Meta-analysis of Comparative Studies.Cell transplantationPooled it
- Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial.Clinical drug investigation · 2016Trial
- Microglial Polarization and Therapeutic Strategies in Post-stroke Neuroinflammation.Neurology and therapy · 2025Review
- 3D-Printed Oral Disintegrating Films of Brain-Targeted Acetyl Salicylic Acid Nanoparticles for Enhanced CNS Delivery in Ischemic Stroke.Pharmaceutics · 2025Article
- Therapeutic spectrum of Piperine in ischemic stroke: a literature review.Molecular biology reports · 2025Review
- HCNS neuroscience & therapeutics · 2025Article
- Revolutionizing Stroke Care: Nanotechnology-Based Brain Delivery as a Novel Paradigm for Treatment and Diagnosis.Molecular neurobiology · 2025Review
- Nanotechnology-Enhanced Naloxone and Alternative Treatments for Opioid Addiction.ACS pharmacology & translational science · 2024Review
- Investigating the Pharmacological Mechanisms of Total Flavonoids fromInternational journal of molecular sciences · 2024Article
- Stem cell therapy as a promising approach for ischemic stroke treatment.Current research in pharmacology and drug discovery · 2024Review
- Neuroprotective effect ofFrontiers in pharmacology · 2024Article
- Intraarterial Transplantation of Mitochondria After Ischemic Stroke Reduces Cerebral Infarction.Stroke (Hoboken, N.J.) · 2023Article
- Chlorogenic acid promotes angiogenesis and attenuates apoptosis following cerebral ischaemia-reperfusion injury by regulating the PI3K-Akt signalling.Pharmaceutical biology · 2022Article
- Studying molecular signaling in major angiogenic diseases.Molecular and cellular biochemistry · 2022Review
- Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke.Molecular pharmaceutics · 2022Article
- Integrative physiological assessment of cerebral hemodynamics and metabolism in acute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Review
- Clinical Significance of PAC-1, CD62P, and Platelet-Leukocyte Aggregates in Acute Ischemic Stroke.Bulletin of experimental biology and medicine · 2022Article
- Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Acute ischemic stroke (AIS) is the fourth leading cause of death and the leading cause of adult disability in the USA. AIS most commonly occurs when a blood vessel is obstructed leading to irreversible brain injury and subsequent focal neurologic deficits. Drug treatment of AIS involves intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator [rtPA]). Intravenous alteplase promotes thrombolysis by hydrolyzing plasminogen to form the proteolytic enzyme plasmin. Plasmin targets the blood clot with limited systemic thrombolytic effects. Alteplase must be administered within a short time window to appropriate patients to optimize its therapeutic efficacy. Recent trials have shown this time window may be extended from 3 to 4.5 hours in select patients. Other acute supportive interventions for AIS include maintaining normoglycemia, euthermia and treating severe hypertension. Urgent anticoagulation for AIS has generally not shown benefits that exceed the hemorrhage risks in the acute setting. Urgent antiplatelet use for AIS has limited benefits and should only promptly be initiated if alteplase was not administered, or after 24 hours if alteplase was administered. The majority of AIS patients do not receive thrombolytic therapy due to late arrival to emergency departments and currently there is a paucity of acute interventions for them. Ongoing clinical trials may lead to further medical breakthroughs to limit the damage inflicted by this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.